Inhibition of TNF-Î± synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69
Fiebich, BL, Heinrich, M, Hiller, KO & Kammerer, N 2001, 'Inhibition of TNF - a synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69', Phytomedicine, vol. 8, no. 1, pp. 28-30.
Published version available from:
Harpagophytum procumbens (Devil's Claw) is often used in the supportive treatment of inflammatory and degenerative diseases of the skeletal system. Here we studied the anti-inflammatory properties of the Harpagophytum extract SteiHap 69 (Steiner Harpagophytum procumbens extract 69) on primary human monocytes, a useful model of peripheral inflammation. After eliminating lipopolysaccharides of bacterial origin, SteiHap 69 prevented the LPS-induced synthesis of tumour necrosis factor alpha (TNFÎ±) in stimulated primary human monocytes in a dose-dependent manner. Harpagide and harpagoside had no effect on LPS-induced TNFÎ±-release. Our data provides evidence that the Harpagophytum extract SteiHap 69 has anti-inflammatory properties. Further studies are required in order to elucidate the molecular mechanism of Devil's claw anti-inflammatory effects.